Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Mol Cancer Ther. 2005;4:503
© 2005 American Association for Cancer Research

Article on roscovitine and P-Ser-46-p53

In the article on roscovitine inducing P-Ser-46-p53 and its target in the January 2005 issue (1), the labeling in Fig. 4 appeared incorrectly. The correct figure is below.



View larger version (56K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 4. Strong induction of p53 protein in human cells exposed to roscovitine. Top, whole cell extracts prepared from human control cells and cells exposed to 20 µmol/L roscovitine were separated on a 10% SDS gel (30 µg/lane). Transfer and immunoblotting conditions as in Fig. 2. Blots were incubated with monoclonal anti-p53 antibodies DO-1 and sequentially with anti-PARP-1, anti-PCNA and anti-actin antibodies. The partial lack of the 89-kDa band in the third lane is due to air bubble generation and inappropriate protein transfer. Lysate of human cervix carcinoma HTB-31 cells expressing high levels of mutant p53 was loaded in the last lane. Bottom, the concentration of total p53 in cell extracts prepared from control cells and cells treated with 20 µmol/L roscovitine for the indicated periods of time were determined by ELISA. For the standard curve, p53 protein within the range from 0 to 8 ng/mL was used. The assay was done in duplicate according to the manufacturer's procedure.

 
References

  1. Wesierska-Gadek J, Gueorguieva M, Horky M. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol Cancer Ther 2005;4(1):113–24.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online